The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study.
M O
MO
Becker
C
C
Brückner
H U
HU
Scherer
N
N
Wassermann
J Y
JY
Humrich
L G
LG
Hanitsch
U
U
Schneider
A
A
Kawald
K
K
Hanke
G R
GR
Burmester
G
G
Riemekasten
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D053645:Interleukin-2 Receptor alpha Subunit / Q000037:antagonists & inhibitors; D008297:Male; D008875:Middle Aged; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D045743:Scleroderma, Diffuse / Q000188:drug therapy*; D012867:Skin / Q000473:pathology; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; C508017:IL2RA protein, human; D007166:Immunosuppressive Agents; D053645:Interleukin-2 Receptor alpha Subunit; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab